

## **CardioGenics Announces Retention of Redington, Inc. to Provide Investor Relations Services for the Company**

MISSISSAUGA, Ontario - May 20, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the IVD segment of the Point-Of-Care (POC) diagnostic market, has retained Redington, Inc. to provide investor relations and financial communications services for the Company. Shareholder inquiries can now be directed to:

Redington, Inc.

CardioGenics Desk

Tel: 203.222.7399

Fax: 203.222.1819

E-Mail: [info@redingtoninc.com](mailto:info@redingtoninc.com)

[www.redingtoninc.com](http://www.redingtoninc.com)

Redington specializes in investor relations and financial communication services for the life sciences market and has rendered financial communications services for companies such as Amgen, Celgene Corporation, Quidel Corporation, Crucell and Medware Information Systems Inc.

Wolfe Axelrod, which has been handling investor relations functions for the Company, will continue to provide their services, which will now be re-focused on the Company's existing stockholder base.

Dr. Yahia Gawad, CEO of CardioGenics, stated, "We are very pleased to have Redington Inc. undertaking investor relations for the Company. Their focus on life science companies places them in an excellent position to introduce CardioGenics to potential investors who are actively seeking investment opportunities in the life sciences area."

### *About CardioGenics Holdings Inc.*

Through its CardioGenics subsidiaries, the Company develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. It has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada.

*Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "Anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.*

SOURCE CardioGenics Holdings Inc.